PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients

Abstract

In Alzheimer’s disease (AD), the control of translation is dysregulated, precisely, two opposite pathways: double‐stranded RNA‐dependent protein kinase (PKR) is up‐regulated and mammalian target of rapamycin (mTOR) is down‐regulated. These biochemical alterations were found at the periphery in lymphocytes of AD patients and were significantly correlated with cognitive and memory test scores. However, the molecular crosslink between these two opposite signalling pathways remains unknown. The tumour suppressor p53 and Redd1 (regulated in development and DNA damage response) could be two downstream targets of active PKR to explain the breakdown of translation in AD patients. In this study, the protein and gene levels of p53 and Redd1 were assayed in lymphocytes of AD patients and in age‐matched controls by Western blotting and RT‐PCR. Furthermore, correlations were analysed with both the level of active PKR and the Mini Mental State Examination score (MMSE). The results show that the gene and protein levels of p53 and Redd1 were significantly increased about 1.5‐fold for both gene and Redd1 protein and 2.3‐fold for active p53 in AD lymphocytes compared to age‐matched controls. Furthermore, statistical correlations between proteins and genes suggest that active PKR could phosphorylate p53 which could induce the transcription of Redd1 gene. No correlations were found between MMSE scores and levels of p53 or Redd1, contrary to active PKR levels. PKR represents a cognitive decline biomarker able to dysregulate translation via two consecutive targets p53 and Redd1 in AD lymphocytes.

Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer

“…Indeed, the combination groups showed not only significantly reduced tumor burden as measured by photon intensity, compared with vehicle-treated mice and mice treated with AZA alone, but also increased survival for both 0.3 mg/kg (data not shown) and 0.1 mg/kg doses of talazoparib paired with 0.5 mg/kg of AZA (Figures 7A–C). In this model, the leukemia cells home preferentially to the bone marrow, with little evidence of disease in peripheral blood and spleen, as previously described (Damjanac et al, 2009). While mice treated with 0.3 mg/kg and 0.5 mg/kg (data not shown) BMN 673 in the drug combination lost weight, mice treated with 0.1 mg/kg in the combination gained weight during the study, demonstrating that this dosing regimen is again well tolerated (Figure 7D).…”

Genome-wide analysis of H4K5 acetylation associated with fear memory in mice

“…Recent studies have linked Tsc1/2 dysregulation to cognitive deficits associated with tuberous sclerosis and identified this gene as a potential target to treat autism [62,63]. Ddit4 has also been implicated in Alzheimer’s disease and is therefore highly relevant for memory processes [64,65]. …”

Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner

“…Increased REDD1 expression in neurodegenerative diseases such as Parkinson´s and Alzheimer´s disease leads to permanent inhibition of mTOR and thereby cellular death [22,23]. On the contrary, reduced REDD1 expression and constitutive mTOR signalling is found in cancer patients [16,18].…”